The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...

As the Biden presidency winds down, the administration touted its Cancer Moonshot accomplishments, including regulatory action against forever chemicals and ethylene oxide, expanded access to cancer ...

The FDA has banned the use of a synthetic red dye used in oral medicines, as well as foods and dietary supplements, more than ...

French pharma major Sanofi's participation at the JP Morgan Healthcare Conference was marked by a comprehensive overview of its position in 2024 and its strategic vision for the future.

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second inflammatory bowel disease (IBD) condition, Crohn's disease (“CD”), in the United ...

The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease ...

The US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz), from US pharma major Eli Lilly, for the ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

Indianapolis: Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved Omvoh ...

Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment ...